JHOP - February 2020 Vol 10, No 1

Robert Mancini, PharmD, BCOP; Mallori Hooker, NP-C, AOCNP, BMTCN; William Kreisle, MD

Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents

Zachery Halford, PharmD, BCOP, BCPPS; Megan Park, PharmD, MBA, DPLA

Subcutaneous versus Intravenous Granulocyte Colony-Stimulating Factor to Enhance Neutrophil Engraftment in Patients Undergoing Hematopoietic Stem-Cell Transplant

Samantha L. Ellingson, PharmD, BCPS; Diwura Owolabi, PharmD, BCOP; Susan Wheelis, PharmD, BCOP; Carrie S. Oliphant, PharmD, FCCP, BCPS, BCCP; Yasser Khaled, MD

Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing

Joshua A. Roth, PhD, MHA; Theo deVos, PhD; Scott D. Ramsey, MD, PhD

FDA Updates

Recent Cancer Drugs Approved by the FDA

ASH Highlights

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome

Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia

All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy

Tazemetostat, First-in-Class EZH2 Inhibitor, Shows Impressive Activity in Relapsed or Refractory Follicular Lymphoma

Nivolumab Monotherapy as Bridge to Transplant in Patients with Relapsed or Refractory Hodgkin Lymphoma

Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma

Symptom Management Overview

Clostridium difficile Infection Management in Adults Undergoing Stem-Cell Transplant

Tetyana Melnyk, PharmD